Swiss Cardio Technologies AG

Cardioplexol™ Demonstrates Safety and Efficacy in Phase 3 Trial for Cardiac Surgery

- A pivotal phase 3 non-inferiority trial has confirmed the safety and efficacy of Cardioplexol™, a new low-volume cardioplegic solution, compared to standard Buckberg blood cardioplegia in cardiac surgeries. - Cardioplexol™ showed significant advantages including faster cardiac arrest (11 vs 71 seconds), reduced cross-clamp time, lower defibrillation rates (10% vs 52%), and decreased need for post-operative inotropic support. - Following successful clinical validation, Cardioplexol™ received marketing authorization in Switzerland in September 2023 and in 10 European countries in April 2024.